Le Lézard
Classified in: Health
Subjects: TRI, FDA, FVT

Nashville surgeon to be the first in Tennessee to surgically implant the first and only trifocal lens in the U.S.


NASHVILLE, Tenn., Aug. 30, 2019 /PRNewswire/ -- Jeffrey D. Horn, MD, owner of Vision For Life in Nashville, is set to be the first to surgically implant the new FDA approved PanOptix Trifocal Intraocular Lens on Wednesday, Sept. 4, and you are invited to the procedure and interview the surgeon and the patient pre- and post-operatively.

A limited number of media will also be granted access to video the procedure.

The first surgery since gaining FDA approval is slated to begin at 11 a.m. at The Eye Surgery Center of Middle Tennessee. Below is the address and the tentative interview schedule. Times may vary as it's a busy surgery day.

210 25th Ave. N., Suite 920., Nashville, TN 37203

8 a.m. ? 8:15 a.m. ? Dr. Horn pre-op interview

8:45 a.m. ? 9:10 a.m. ? Patient pre-op interview

10:40 a.m. ? 10:55 a.m. ? Dr. Horn pre-op interview

11 a.m. ? 11:30 a.m. ? Surgery (cameras will be allowed in O.R. on a limited basis)

11:30 a.m. ? 11:45 a.m. ? Dr. Horn post-op interview

11:45 a.m. ? 12 p.m. ? Patient post-op interview

"This is an extremely exciting advancement in the treatment of cataract surgery," Horn said. "The trifocal lens corrects vision at all distances and is quite simply the best lens I have ever implanted."

The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the U.S., including Vision For Life here in Nashville, being led by Dr. Horn.

With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision. The results also showed high patient satisfaction with more than ninety-nine percent of PanOptix patients saying they would choose the same lens again.

According to Alcon, the manufacturer of the PanOptix lens, more than 4 million cataract surgeries are performed each year in the U.S., which is projected to increase by more than 16 percent by the end of 2024.

Cataracts are the most common age-related eye condition and the leading cause of preventable blindness. Twenty million people in the U.S. age 40 and older have cataracts, but they can be reversed with surgery. Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an intraocular lens or IOL. More than 98 percent of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.

"It is, quite simply, the best lens I've ever implanted." Horn said. "The results of the trial are incredible."

IF YOU WOULD LIKE TO JOIN DR. HORN ON WEDNESDAY FOR THE PANOPTIX LENS IMPLANT SURGERY, PLEASE CONTACT MATT HUDSON AT 615.482.4296 or matt@brassadvertising.com

CONTACT
Matt Hudson/Brass Advertising   
615.482.4296 
matt@brassadvertising.com

SOURCE Jeffrey D. Horn, MD Vision For Life


These press releases may also interest you

at 00:21
Lupin Pharmaceuticals Inc. is voluntarily recalling all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg to the consumer level. As part of the ongoing assessment and continuation of the dialog with the FDA, additional...

at 00:01
Sacrificing one's health to vote in the November election: 60% are willing to risk their health to vote in person, according to the latest healthinsurance.com consumer pulse survey. 63% of Americans don't think healthcare should be a political issue....

at 00:00
45% of global consumers say healthcare is one of the top three reasons for living in a city 69% of global consumers are more focused on mental health and well being 43% of global consumer expect businesses to be accountable for their environmental...

at 00:00
R3 International is now offering effective stem cell therapy for Crohns disease, Ulcerative Colitis and IBD with a new program in Mexico. The new program provides up to 200 million stem cells for patients, with treatment starting at only $2975....

7 jui 2020
Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved INQOVI® (decitabine and cedazuridine) tablets. The three companies...

7 jui 2020
Note: All times local Ottawa, Ontario Private meetings. 11:00 a.m. The Prime Minister will address Canadians on the COVID-19 situation, and a media availability will follow. Room 225 West Block Parliament Hill Notes for media: Open coverage Media...



News published on 30 august 2019 at 12:48 and distributed by: